257cardial infarction treated with a beta-blocker. Support for a polypill approach. Curr Med Res
Opin. 2011;27:1563–70.- Indian Polycap S, Yusuf S, Pais P, et al. Effects of a polypill (Polycap) on risk factors in
middle aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, ran-
domised trial. Lancet. 2009;373:1341–51. - Malekzadeh F, Marshall T, Pourshams A, et al. A pilot double-blind randomised placebo
controlled trial of the effects of fixed-dose combination therapy (‘polypill’) on cardiovascular
risk factors. Int J Clin Pract. 2010;64:1220–7. - Soliman EZ, Mendis S, Dissanayake WP, et al. Apolypill for primary prevention of cardiovas-
cular disease: a feasibility study of the World Health Organization. Trials. 2011;12:3. - Rodgers A, Patel A, Berwanger O, et al. An international randomised placebo-controlled trial
of a four-component combination pill (“polypill”) in people with raised cardiovascular risk.
PloS One. 2011;6:e19857. - Yusuf S, Pais P, Sigamani A, et al. Comparison of risk factor reduction and tolerability of a
fulldosepolypill (with potassium) versus low-dose polypill (Polycap) in individuals at high
risk of cardiovascular diseases: the second Indian Polycap study (TIPS-2) investigators. Circ
Cardiovasc Qual Outcomes. 2012;5:463–71. - Thom S, Poulter N, Field J, et al. Effects of a fixed-dose combination strategy on adherence
and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical
trial. JAMA. 2013;310:918–29. - Hermida RC, Ayala DE, Fernandez JR, et al. Chronotherapy improves blood pressure con-
trol and reverts the nondipper pattern in patients with resistant hypertension. Hypertension.
2008;51:69–76. - Almirall J, Comas L, Martinez-Ocana JC, et al. Effects of chronotherapy on blood pres-
sure control in non-dipper patients with refractory hypertension. Nephrol Dial Transplant.
2012;27:1855–9. - KontakAC WZ, Arbique D, et al. Reversible sympathetic overactivity in hypertensive patients
with primary aldosteronism. J Clin Endocrinol Metab. 2010;95(10):4756–61. - Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pres-
sure in patients with resistant hypertension: results from the double-blind, randomized,
placebo- controlled rheos pivotal trial. J Am Coll Cardiol. 2011;58(7):765–73. - Esler MD, Krum H, Sobotka PA, SYMPLICITY HTN-2 Investigators, et al. Renal sym-
pathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY
HTN-2 trial): a randomised controlled trial. Lancet. 2010;376(9756):1903–9. - Bhatt DL, Kandzari DE, WW O’N, SYMPLICITY HTN-3 Investigators, et al. A controlled
trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393–401.
15 Public Health Efforts for Earlier Resistant Hypertension Diagnosis...